MedTrace Logo

High-Intensity Interval Training vs Moderate-Intensity Continuous Training in Phase II Cardiac Rehabilitation

NCT07619664 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-06-02

No results posted yet for this study

Summary

This randomized controlled trial aims to compare the effects of High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) in patients undergoing Phase II cardiac rehabilitation after coronary artery disease or post-angioplasty. A total of 66 participants will be randomly allocated into two groups: HIIT (n=33) and MICT (n=33). The intervention will be conducted 3 times per week using treadmill-based exercise protocols under heart rate monitoring. Primary outcomes include changes in left ventricular ejection fraction, functional capacity measured by 6-minute walk test, and lipid profile parameters before and after intervention. Secondary assessment includes health-related quality of life (HRQoL). The study aims to determine which exercise modality provides superior cardiovascular and functional improvement in stable cardiac patients during supervised rehabilitation.

Conditions

Interventions

BEHAVIORAL

High-Intensity Interval Training

Participants will perform supervised treadmill-based high-intensity interval training 3 times per week. Each session includes 10 minutes warm-up, 4 intervals of 4 minutes at 85-95% heart rate reserve, 4 minutes active recovery at 50-60% heart rate reserve, followed by 5 minutes cool-down.

BEHAVIORAL

Moderate-Intensity Continuous Training

Participants will perform supervised treadmill-based continuous exercise 3 times per week at 65-75% heart rate reserve for 30-45 minutes, including warm-up and cool-down periods.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Arjumand Bano, MSPT · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07619664 on ClinicalTrials.gov